Searchable abstracts of presentations at key conferences in endocrinology

ea0050p266 | Neuroendocrinology and Pituitary | SFEBES2017

Patterns of recurrence, response to treatment and mortality in patients with malignant phaeochromocytomas and paragangliomas. – a single centre experience

Abdel-Aziz Tarek , Chung Teng-Teng , Bomanji Jamshed , Gaze Mark , Kurzawinski Tom

Introduction: Histology is a poor predictor of the malignant potential of phaeochromocytomas and paragangliomas (PPGL) and only the presence of distant metastasis confirms malignancy. This study reviews patterns of recurrence, treatment and mortality in patients with malignant PPGL presenting to our department at UCLH over 30 years.Materials and Methods: In our series of 128 patients with PPGL, 26 (20%) with maligna...

ea0050p266 | Neuroendocrinology and Pituitary | SFEBES2017

Patterns of recurrence, response to treatment and mortality in patients with malignant phaeochromocytomas and paragangliomas. – a single centre experience

Abdel-Aziz Tarek , Chung Teng-Teng , Bomanji Jamshed , Gaze Mark , Kurzawinski Tom

Introduction: Histology is a poor predictor of the malignant potential of phaeochromocytomas and paragangliomas (PPGL) and only the presence of distant metastasis confirms malignancy. This study reviews patterns of recurrence, treatment and mortality in patients with malignant PPGL presenting to our department at UCLH over 30 years.Materials and Methods: In our series of 128 patients with PPGL, 26 (20%) with maligna...

ea0089t8 | Trials In Progress | NANETS2022

Phase II Trial Evaluating [177Lu]Lu-DOTA-TATE in Adolescents with Somatostatin Receptor (SSTR)-positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), Pheochromocytomas and Paragangliomas (PPGLs)

Chauhan Aman , Sue O'Dorisio M. , Gaze Mark , Sabado Constantino , Brouri Fazia , Xu Lingfei

Background: GEP-NETS and PPGLs in pediatric patients are rare; however, recognition of these diseases has increased recently. 10–20% of pediatric patients with GEP-NETs and up to 47% of pediatric patients with PPGLs present with metastatic disease at diagnosis. The disease is often unresectable with poor prognosis, and very few non-surgical therapies are approved for these patients. Due to paucity of data surrounding treatments for pediatric patients with advanced GEP-NET...

ea0038p165 | Neoplasia, cancer and late effects | SFEBES2015

Lutetium ablation therapy as treatment for recurrent metastatic bladder paraganglioma

Abhayaratna Sachith , Ojewuyi Taofeek , Gaze Mark , Kar P , Baldeweg Stephanie E

We present the case of a 53 year old gentleman with recurrent bladder paraganglioma. He presented initially in 2010 with headache and blurred vision when passing urine. The tumour was surgically removed, BP normalized and his postoperative MIBG-scan was normal. The patient presented with hypertensive crisis 4 years later with a suspicion of tumor recurrence, confirmed biochemically and radiologically. Treatment with phenoxybenzamine and bisoprolol resulted in adequate BP contr...

ea0077oc2.1 | Endocrine Cancer and Late Effects | SFEBES2021

Outcomes of surgery and treatment with selective RET TK inhibitor Selpercatinib in children with MEN2 and advanced MTC.

Kurzawinski Tom , Hubbard Jonathan , Abdel Aziz Tarek , Butler Colin , Brain Caroline , Beale Tim , Gaze Mark , Ross Emma , Stoneham Sarah , Hulse Tony , Simpson Kate , Proctor Ian , Cattaneo Elene , Gevers Evelien , Marshall Lynley , Shankar Ananth

Background: Patients with Multiple Endocrine Neoplasia type 2 (MEN2) without previous family history often present late with advanced Medullary Thyroid Cancer (MTC). Surgery is not always curative but RET tyrosine kinase pathway is a potential target for molecular treatment for progressive MTC.Methods: Retrospective review of clinical, genetic, biochemical (calcitonin, CEA) and imaging (US, CT/MRI, Gallium Dotate) data of children with MEN2 who developed...